Intravenous recombinant tissue plasminogen activator (r-tPA) was approved for use in acute
ischemic stroke in the United States in 1996. Approximately 2% to 5% of patients with acute …

Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients
with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide …

Background Hemorrhagic transformation (HT) following reperfusion therapies for acute
ischaemic stroke often predicts a poor prognosis. This systematic review and meta-analysis …

The optimal blood pressure (BP) management in acute ischaemic stroke (AIS) and acute
intracerebral haemorrhage (ICH) remains controversial. These European Stroke …

Hypertension is the most important modifiable cause of cardiovascular (CV) disease and all-
cause mortality worldwide. Despite the positive correlations between blood pressure (BP) …

Summary Background Only 2–5% of patients who have a stroke receive thrombolytic
treatment, mainly because of delay in reaching the hospital. We aimed to assess the efficacy …

Background and Purpose—There are few validated models for prediction of risk of
symptomatic intracranial hemorrhage (sICH) after intravenous tissue-type plasminogen …

Background and Purpose—Numerous contraindications included in the license of alteplase,
most of which are not based on scientific evidence, restrict the portion of patients with acute …

Reperfusion therapies are the mainstay of acute ischemic stroke (AIS) treatments and
overall improve functional outcome. Among the established complications of intravenous …

Background and Purpose—High blood pressure (BP) is associated with poor outcome and
the occurrence of symptomatic intracranial hemorrhage in acute ischemic stroke. Whether …